Glenmark Pharmaceuticals Ltd
GLEN.IN
$12.47
Closing
▼-1.72%
1D
▲22.00%
YTD
Market cap
$3.51B
52 week high
$12.81
52 week low
$6.07
Volume
1,139,829
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$3.51B
Analysts' Rating
HOLD
Price Target (Mean)
Unable to collect data for some field(s).
Total Analysts
0
P/E
Operating Margin
-0.14%
Beta
1.15
Revenue Growth (Annual)
-12.63%
52 week high
$12.81
52 week low
$6.07
Div. Yield
0.24%
EPS Annual Growth
0.00
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Glenmark Pharmaceuticals Limited is an India-based global pharmaceutical company. The Company is focused on building a global formulation business with branded, generics and over the counter (OTC) segments in the therapy areas of dermatology, respiratory and oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. Its product portfolio includes topical products, liquids, respiratory MDI/DPI, complex injectables and biologics, and oral solids. The Company has a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand, Tiogiva in the United Kingdom and Tavulus in Spain, for the treatment of chronic obstructive pulmonary disease. Ryaltris, the Company’s first branded specialty product globally, is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis.
